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ABSTRACT: The preparation of hetero-nanoparticles (NPs) with doxorubicin (DOXO) and cyclopamine (CYP) conjugates is pre-
sented. Biological evaluation on A431 cell lines confirms the maintenance of the activity of the parental drugs. The in vivo study 
shows that self-assembled NPs reduce tumour growth and toxicity of chemotherapy. 
The use of self-assembled nanoparticles (NPs) is a challenging 
strategy that could result in a useful and smart approach to ef-
fectively treat cancer.
1
 In particular, we have recently reported 
the preparation of a novel class of squalene conjugates with 
paclitaxel, podophyllotoxin, camptothecin and epothilone A.
2 
The compounds obtained were characterized by a squalene tail 
that makes them able to self-assemble in water, and by a drug 
unit connected via a disulfide-containing linker to secure the 
release inside the cell. The need to trace the delivery of the 
nanoassemblies and to demonstrate the internalization of the 
drugs prompted us to prepare fluorescent hetero-
nanoassemblies composed by a paclitaxel-squalene conjugate 
and fluorescein-squalene conjugate.
3
 Following the increasing 
interest of targeting cancer stem cells (CSCs)
4,5
 we moved 
forward and we demonstrated that cyclopamine – a hedgehog 
signaling pathway inhibitor - and paclitaxel conjugates self-
assemble to generate hetero-NPs that show combined efficacy 
in the treatment of three different cancer cell lines. The use of 
ternary combination with the addition of a dye-squalene con-
jugate secured the obtainment of fluorescent NPs that allowed 
the cellular internalization by confocal microscopy and super 
resolution dSTORM.
6
 Besides the recent advances in cancer 
treatment, classical chemotherapy still exhibits two major pit-
falls, high toxicity and limited efficacy possibly resulting in 
tumour resistance and subsequently cancer relapse.
7
 Pursuing 
our interest in self-assembled nanoparticles,
8
 we investigated 
the combination of cyclopamine (CYP, Hedgehog pathway 
inhibitor
4
) and doxorubicin (DOXO) conjugates (Chart 1) with 
the aim to demonstrate the formation of hetero-NPs that could 
improve the performance given by the use of the simple paren-
tal drugs. 
 
 
 
 
Chart 1. Structure of the used anticancer compounds. In red the anchor 
point for the functionalization. 
 
 
Specifically, we decided to investigate the combination of cy-
clopamine-squalene (CYP-SQ) derivative 1, a conjugate found 
to be active on different types of cancer cells,
6
 with doxorubi-
cin-squalene (DOXO-SQ) 2, described by Couvreur and some 
of us
7
 as able to improve the anticancer efficacy and the thera-
peutic index of DOXO (Chart 2).  
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NPs Composition 
Components 
molar ratio and concen-
tration 
Mean diameter 
(nm ± S.D.) 
Polydispersity 
index 
Zeta potential 
(mV ± S.D.) 
NP0 CYP-SQ 10 µM 127.8±0.723 0.106 +44.1±2.048 
NP1 CYP-SQ/DOXO-SQ 1:1 (10 µM, 10 µM) 126.9±1.108 0.102 +61.6±4.18 
NP2 CYP-SQ/DOXO-SQ 5:1 (10 µM, 2 µM) 129.4±1.589 0.109 +50.9±0.404 
NP3 CYP-SQ/DOXO-SQ 10:1 (10 µM, 1 µM) 127.7±0.734 0.106 +56.8±2.66 
NP4 DOXO-SQ 10 µM 395.4±6.739 0.122 +58.1±0.643 
 
Table 1. NPs composition and characterization 
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Chart 2. Structure of the drug-squalene conjugates CYP-SQ and DOXO-
SQ. 
 
Hetero-NPs were obtained by mixing two squalene conjugates, 
CYP-SQ (1) and DOXO-SQ (2) (Chart 2), prepared according 
to the previously described approaches.
6,7
 All NPs were pre-
pared by solvent-displacement method,
9
 using THF as organic 
solvent and without adding any surfactant. 
1 and 2 were co-nanoprecipitated at 1:1, 5:1, 10:1 molar ratios 
(Table 1, NP1, NP2 and NP3 respectively) with a constant 
concentration of 1, giving a suspension of narrow monodis-
persed NPs. 1 and 2 were also separately nanoprecipitated to 
obtain NPs of CYP-SQ or DOXO-SQ alone (Table 1, NP0 and 
NP4). All the formulations were characterized in terms of 
mean diameter and zeta potential of the NPs. As showed in 
Table 1, CYP-SQ and DOXO-SQ alone spontaneously self-
assembled in water forming NPs; however, DOXO-SQ NPs 
displayed a larger mean diameter of about 400 nm. When 
DOXO-SQ was formulated with an equimolar amount of 
CYP-SQ (NP1), the mean size drastically reduced from 400 to 
about 130 nm; in these conditions DOXO-SQ probably took  a 
different sovramolecular organization and mutual interactions 
between the two squalene conjugates caused the formation of 
smaller nanoparticles. The addition of DOXO-SQ in various 
molar ratios did not influence the mean size of CYP-SQ NPs. 
The zeta potential of all NPs is highly positive; for NPs con-
taining DOXO-SQ it is higher than the one of CYP-SQ-
containing NPs. As reported in the Supporting Information, 
after 4-weeks storage at 4°C in water, no appreciable NPs size 
and/or zeta potential changes were detected by Dynamic Light 
Scattering (DLS) for all formulations (except for DOXO-SQ 
NP mean diameter) and no NPs aggregation was observed. 
After dilution with fetal bovine serum, NP1 did not show ag-
gregation, even after 24 h at 4°C. On the contrary, the incuba-
tion in PBS 10 mM resulted in an increase of the NP1 mean 
diameter up to about 400 nm (700 nm after 24 h).  
We next investigated in details the effect of the NPs in a cellu-
lar system
10
 with an activated Hedgehog pathway. Specifical-
ly, we used the human epidermoid carcinoma cell line A431, 
which carries a single point mutation in exon 23 of both alleles 
of Patched1 gene, resulting in a proline to leukine substitution 
and subsequent constitutive activation of the Hedgehog path-
way.
11
  In a similar experimental setting, we studied the inhibi-
tion of proliferation and the apoptosis induction upon addition 
of CYP, DOXO and distinct ratios of CYP:DOXO, conjugate 
1, conjugate 2 and distinct ratios of 1 and 2, free or assembled 
in NPs. 
 
                
 
Figure 1. Effect on proliferation (A) and viability (B) in the A431 cancer 
cell line of cyclopamine, doxorubicin (reported as Parental drugs), com-
pounds 1 and 2 not nanoprecipitated (reported as Conjugates) and nano-
precipitated compounds 1 and 2 (reported as NP). Concentration of the 
samples: NP1 (nanoprecipitated CYP-SQ = DOXO-SQ = 10 µM); NP2 
(nanoprecipitated CYP-SQ = 10 µM, DOXO-SQ = 2 µM; NP3 (nanopre-
cipitated CYP-SQ = 10 µM, DOXO-SQ = 1 µM; 1:2 (1:1): CYP-SQ = 
DOXO-SQ = 10 µM; 1:2 (5:1): CYP-SQ = 10 µM, DOXO-SQ = 2 µM; 
1:2 (10:1): CYP-SQ = 10 µM, DOXO-SQ = 1 µM; CYP:DOXO (1:1): 
CYP = DOXO = 10 µM, CYP:DOXO (5:1): CYP = 10 µM, DOXO = 2 
µM, CYP:DOXO (10:1): CYP = 10 µM, DOXO = 1 µM. Statistical sig-
nificance (Student’s t test) compared to Control: ns, p>0.01; *, p < 0.01; 
**, p<0.001; ***, p<0.0001.  
 
DOXO alone at 10 µM (Figure 1A) was able to inhibit prolif-
eration of more than 50%, and the addition of CYP further en-
hanced the cytostatic effect. The combination of 1 and 2 in 1:1 
molar ratio also resulted in inhibition of proliferation, although 
to a lesser extent. Interestingly, when NP1 was used, cell pro-
liferation is essentially entirely blocked. The same trend ap-
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 pears when investigating cell death, with CYP and derivative 1 
not causing significant apoptosis, DOXO and derivative 2, 
alone or in combination with CYP or derivative 1 inducing 
apoptosis in 30-60% of the cells, while when assembled in 
NP1, practically all cells are dead (Figure 1B). Notably, while 
apoptosis is only observed at the 1:1 ratio of CYP:DOXO or 
of derivatives 1 and 2, inhibition of proliferation could be ob-
served also at the ratio 5:1, potentially indicating that either 
lower concentration of DOXO or derivative 2  is necessary for 
the cytostatic function, or that apoptosis is a later stage event 
in this system. A time course analysis of proliferation and 
apoptosis would discriminate between the two options, but this 
is out of the scope of this work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Dose response of equimolar concentrations of CYP and DOXO 
as parental drugs (CYP:DOXO), conjugates (1:2) or assembled in nano-
particles (NP1). The effect on proliferation (A) and their cytotoxic poten-
tial (B) is estimated by FACS analysis of BrdU incorporation and cleaved 
PARP immunostaining respectively. Concentration of the samples: NP1 
(nanoprecipitated CYP-SQ = DOXO-SQ = 10 µM); 1:2 (1:1): CYP-SQ = 
DOXO-SQ = 10 µM; CYP:DOXO (1:1): CYP = DOXO = 10 µM. Statis-
tical significance (Student’s t test) compared to the control: ns, p>0.01; *, 
p < 0.01; **, p<0.001; ***, p<0.0001. 
 
Given the strong cytostatic and cytotoxic effect of the 10 µM 
equimolar concentration of CYP:DOXO and 1 and 2, free or 
assembled in NP1, we sought to investigate the dose response 
of A431 cells to these formulations, so as to define the lowest 
concentration required for a toxic effect. As shown in Figure 
2, NP1 has a significant cytotoxic and cytostatic effect already 
at 2.5 µM, while the free drugs require at least 3-fold higher 
concentration to induce apoptosis. Small differences in the 
percentage of proliferating cells treated with 10 µM of com-
pounds in the sets of experiments presented in the figures 1A 
and 2A are a result of difference in confluence, since the first 
set of experiments was performed in 6-well plates and the lat-
ter in 24-well plates. To conclude, our results show that the 
combination of the compounds 1:2 assembled in NP1 exhibit 
strong cytotoxic and cytostatic effect on cells requiring 
Hedgehog signaling even at low concentrations.  
Given the very promising results obtained by the in vitro ex-
periments using cell lines, we sought to investigate whether 
these results could also be observed in vivo, now investigating 
both the antitumoral activity and the toxicity of the formula-
tion. We used a xenograft model, injecting A431 cells into the 
flank of immunosuppressed mice, as detailed in Supporting 
Information. When tumours reached 3 mm in diameter, mice 
were administered intraperitoneally twice weekly equimolar 
concentrations (4 mg/kg of derivative 1 and 5mg/kg of deriva-
tive 2) of 1, 2, and 1:2 free or assembled in NP1, or solely the 
vehicle. Strikingly, when the derivative 2 is injected as a free 
drug, alone or together with 1, it induces very high toxicity 
and the mice die or have to be sacrificed due to weight loss 
and general health deterioration less than a week after treat-
ment initiation (Figure 3A). The derivative 1 alone is not tox-
ic, but does not have an effect on tumour growth. Although, 
when the same concentration of 1:2 is administered as self-
assembled NPs, there is no toxicity and there is a significant 
delay in tumour growth compared to the control mice (Figure 
3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. In vivo effect of equimolar concentration of CYP and DOXO 
conjugates, alone or in combination, or assembled in nanoparticles (NP1). 
(A) Kaplan Meier survival plot of mice upon treatment-administration, as 
indicated, twice weekly. Note that conjugate 2 alone or in combination 
with conjugate 1 exhibits high toxicity. (B) Follow up of tumour size over 
time, upon treatment as described in (A). 20 random images per tumour 
form 3 separate tumours were counted. (C) Representative immunofluo-
rescence images of tumours from mice treated with NP1 or vehicle, 
stained for pH3 labeling cells undergoing mitosis. Note the inhibition of 
proliferation upon treatment with NP1. The antibodies are colour-coded. 
(D) Histogram illustrating the quantification of proliferating cells in mice 
treated with NP1 or vehicle, as illustrated in (C). Results are expressed as 
pH3+ cells per optical field. (E) Representative mosaic immunofluores-
cent images of tumours from mice treated with NP1 or vehicle, stained 
with Keratin 14 indicating differentiated cancer cells and vimentin label-
ing tumour-associated fibroblasts and cells undergone epithelial-
mesenchymal transition. Note the striking difference in the differentiation 
of the tumours. The antibodies are colour-coded. (F) Histogram illustrat-
ing the quantification of differentiated areas in tumours from mice treated 
with NP1 or vehicle, based on the expression of Keratin 14. 20 random 
images per tumour form 3 separate tumours were counted.  Concentration 
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 of the samples: NP1: CYP-SQ = DOXO-SQ = 10 µM; 1:2(1:1): CYP-SQ 
= DOXO-SQ =10 µM; 1 = 10 µM; 2 = 10 µM. Statistical significance 
(Student’s t test): ns, p>0.01; ***, p<0.0001. Scale bars: Panel B, 100 µm; 
Panel E, 1000 µm. 
 
Microscopic analysis of tumours from control mice and mice 
treated with NP1 3 weeks after treatment showed that the latter 
exhibit very strong inhibition of proliferation (Figure 3C, D), 
and a more differentiated phenotype (Figure 3E, F). The latter 
could have important implications in moderating the metastat-
ic potential, although longer experiments should be performed 
to investigate this possibility. Therefore, our in vivo experi-
ments unambiguously show that self-assembled NPs reduce 
tumour growth and toxicity of chemotherapy; this could ena-
ble the administration of higher doses, thus more effective 
cancer treatment. 
In this paper we reported the formation of hetero-NPs combin-
ing cyclopamine- and doxorubicin-squalene derivatives. DLS 
characterization demonstrated that NPs are narrow monodis-
perse and stable for 4 weeks. In vitro biological evaluation on 
confirmed that the cytotoxic activity of the parental drugs is 
maintained. The efficacy of the nanoformulated drugs is high-
er than the single combination of the conjugates. Importantly, 
the in vivo experiments showed that cyclopamine-doxorubicin 
NPs not only reduce tumour growth, but also significantly de-
crease the toxicity of chemotherapy in mice. This will allow 
the administration of higher doses of chemotherapy, potential-
ly eliminating the more resistant tumour cells and therefore 
leading to more effective treatment. 
The results obtained demonstrated that the approach of the 
self-assembled hetero NPs is a promising  way to treat differ-
ent  types of cancer cells and it makes possible to modulate the 
ratio of the combined drugs. Moreover, these results point out 
the possible application of this approach in the personalized 
therapy. 
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